Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54,711,345
-
Number of holders
-
149
-
Total 13F shares, excl. options
-
67,696,992
-
Shares change
-
+2,139,630
-
Total reported value, excl. options
-
$1,574,192,573
-
Value change
-
+$64,455,944
-
Put/Call ratio
-
18%
-
Number of buys
-
81
-
Number of sells
-
62
-
Price
-
$23.50
Institutional Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q3 2025
As of 30 Sep 2025 Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) had 175 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 67,696,992 shares of stock of the company.
Largest 10 holders included FMR LLC, BlackRock, Inc., Lynx1 Capital Management LP, RTW INVESTMENTS, LP, BAKER BROS. ADVISORS LP, Redmile Group, LLC, MORGAN STANLEY, TORONTO DOMINION BANK, VANGUARD GROUP INC, and Skorpios Trust.
This table shows 175 institutional shareholders of the security as of 30 Sep 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.